ATE383422T1 - Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an crkl zielgerichtet sind - Google Patents
Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an crkl zielgerichtet sindInfo
- Publication number
- ATE383422T1 ATE383422T1 AT02001271T AT02001271T ATE383422T1 AT E383422 T1 ATE383422 T1 AT E383422T1 AT 02001271 T AT02001271 T AT 02001271T AT 02001271 T AT02001271 T AT 02001271T AT E383422 T1 ATE383422 T1 AT E383422T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotides
- myelogene
- crkl
- chronic
- inhibition
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 102100029375 Crk-like protein Human genes 0.000 title 1
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 abstract 1
- 101100291374 Mus musculus Mapk14 gene Proteins 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 102000012500 Proto-Oncogene Proteins c-crk Human genes 0.000 abstract 1
- -1 bcr-abl nucleic acids Chemical class 0.000 abstract 1
- 101150098203 grb2 gene Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/679,437 US7309692B1 (en) | 1996-07-08 | 1996-07-08 | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383422T1 true ATE383422T1 (de) | 2008-01-15 |
Family
ID=24726909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97932167T ATE332369T1 (de) | 1996-07-08 | 1997-07-08 | Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an grb2 zielgerichtet sind |
| AT02001271T ATE383422T1 (de) | 1996-07-08 | 1997-07-08 | Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an crkl zielgerichtet sind |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97932167T ATE332369T1 (de) | 1996-07-08 | 1997-07-08 | Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an grb2 zielgerichtet sind |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7309692B1 (de) |
| EP (2) | EP0912729B1 (de) |
| JP (1) | JP2000514438A (de) |
| AT (2) | ATE332369T1 (de) |
| AU (1) | AU740289B2 (de) |
| CA (2) | CA2259144C (de) |
| DE (2) | DE69738459T2 (de) |
| ES (2) | ES2299536T3 (de) |
| WO (1) | WO1998001547A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062911A2 (en) * | 2000-02-24 | 2001-08-30 | Ribozyme Pharmaceuticals, Inc. | Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses |
| WO2006113679A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
| WO2009149418A2 (en) * | 2008-06-06 | 2009-12-10 | Asuragen, Inc. | Novel compositions for the in vivo delivery of rnai agents |
| CN102105487A (zh) * | 2008-06-20 | 2011-06-22 | 得克萨斯大学体系董事会 | 靶向crkl的肽 |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| CN109963571A (zh) | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| AU2018255352B2 (en) | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for STAT3 inhibition |
| JP7415042B2 (ja) | 2020-10-09 | 2024-01-16 | テナヤ セラピューティクス， インコーポレイテッド | プラコフィリン２遺伝子治療の方法および組成物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621479A5 (de) | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US5094785A (en) | 1986-12-10 | 1992-03-10 | Ciba Corning Diagnostics Corp. | Process for stabilizing liposomes |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
| US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| WO1990012595A1 (en) | 1989-04-18 | 1990-11-01 | Vestar, Inc. | Liposomal targeting of ischemic tissue |
| CA2033725C (en) | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| ES2099718T3 (es) | 1990-07-02 | 1997-06-01 | Hoechst Ag | Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales. |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JPH06508622A (ja) * | 1991-06-18 | 1994-09-29 | テンプル ユニバーシティ−オブ ザ コモンウェルス システム オブ ハイヤーエデュケーション | ｂｃｒ−ａｂ１アンチセンスオリゴヌクレオチドによる白血球増殖の選択的抑制 |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US6001992A (en) | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
| US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| FR2710074B1 (fr) | 1993-09-15 | 1995-12-08 | Rhone Poulenc Rorer Sa | Gène GRB3-3, ses variants et leurs utilisations. |
| AU7845194A (en) | 1993-09-28 | 1995-04-18 | General Hospital Corporation, The | Using antisense oligonucleotides to modulate nerve growth and to reverse beta/A4 amyloid-induced morphology |
| US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
| CA2113494A1 (en) | 1994-01-14 | 1995-07-15 | Lorri Puil | Method for assaying for substances which affect bcr-abl mediated transformation |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5667981A (en) | 1994-05-13 | 1997-09-16 | Childrens Hospital Of Los Angeles | Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein |
| US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| ES2268705T3 (es) | 1995-06-01 | 2007-03-16 | Kishimoto, Tadamitsu | Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1). |
| US6326487B1 (en) | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| AU705644B2 (en) | 1995-08-01 | 1999-05-27 | Novartis Ag | Liposomal oligonucleotide compositions |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| AU4510396A (en) | 1995-12-04 | 1997-06-27 | Human Genome Sciences, Inc. | Growth factor receptor-binding protein 2 homolog |
| US5874224A (en) | 1997-03-11 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Growth factor receptor binding protein |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| GB9711919D0 (en) | 1997-06-09 | 1997-08-06 | Ciba Geigy Ag | Oligonucleotide derivatives |
| ES2212305T3 (es) | 1997-06-23 | 2004-07-16 | Alza Corporation | Polinucleotidos encapsulados en liposomas, composicion y procedimiento. |
| WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
| US6136965A (en) | 1998-07-02 | 2000-10-24 | The Regents Of The University Of California | Deoxynucleic alkyl and alkoxy thiourea compounds |
| US6211162B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
| US6211349B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
| US6323487B1 (en) * | 1999-01-26 | 2001-11-27 | Delphi Technologies, Inc. | IR optical position sensor system |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
-
1996
- 1996-07-08 US US08/679,437 patent/US7309692B1/en not_active Expired - Fee Related
-
1997
- 1997-07-08 DE DE69738459T patent/DE69738459T2/de not_active Expired - Lifetime
- 1997-07-08 AT AT97932167T patent/ATE332369T1/de not_active IP Right Cessation
- 1997-07-08 AU AU35694/97A patent/AU740289B2/en not_active Ceased
- 1997-07-08 AT AT02001271T patent/ATE383422T1/de not_active IP Right Cessation
- 1997-07-08 JP JP10505197A patent/JP2000514438A/ja active Pending
- 1997-07-08 DE DE69736290T patent/DE69736290T2/de not_active Expired - Lifetime
- 1997-07-08 EP EP97932167A patent/EP0912729B1/de not_active Expired - Lifetime
- 1997-07-08 ES ES02001271T patent/ES2299536T3/es not_active Expired - Lifetime
- 1997-07-08 EP EP02001271A patent/EP1234876B1/de not_active Expired - Lifetime
- 1997-07-08 CA CA2259144A patent/CA2259144C/en not_active Expired - Fee Related
- 1997-07-08 CA CA2741501A patent/CA2741501A1/en not_active Abandoned
- 1997-07-08 WO PCT/US1997/010101 patent/WO1998001547A1/en not_active Ceased
- 1997-07-08 ES ES97932167T patent/ES2268731T3/es not_active Expired - Lifetime
-
2002
- 2002-12-20 US US10/327,509 patent/US7220853B2/en not_active Expired - Fee Related
-
2007
- 2007-04-03 US US11/696,015 patent/US7923548B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070238686A1 (en) | 2007-10-11 |
| US20030153526A1 (en) | 2003-08-14 |
| ES2299536T3 (es) | 2008-06-01 |
| AU740289B2 (en) | 2001-11-01 |
| ES2268731T3 (es) | 2007-03-16 |
| US7923548B2 (en) | 2011-04-12 |
| US7309692B1 (en) | 2007-12-18 |
| WO1998001547A1 (en) | 1998-01-15 |
| DE69736290T2 (de) | 2007-07-05 |
| CA2259144C (en) | 2011-09-20 |
| DE69738459D1 (de) | 2008-02-21 |
| AU3569497A (en) | 1998-02-02 |
| DE69736290D1 (de) | 2006-08-17 |
| US7220853B2 (en) | 2007-05-22 |
| ATE332369T1 (de) | 2006-07-15 |
| CA2259144A1 (en) | 1998-01-15 |
| JP2000514438A (ja) | 2000-10-31 |
| EP0912729B1 (de) | 2006-07-05 |
| DE69738459T2 (de) | 2008-12-24 |
| EP0912729A1 (de) | 1999-05-06 |
| EP1234876A1 (de) | 2002-08-28 |
| EP1234876B1 (de) | 2008-01-09 |
| CA2741501A1 (en) | 1998-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69736432D1 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
| EP2796554A3 (de) | Zusammensetzungen zur Behandlung von BCL2-assoziiertem Krebs | |
| WO2004080418A3 (en) | Nucleic acid compounds for inhibiting angiogenesis and tumor growth | |
| ATE508188T1 (de) | Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit | |
| DE60325016D1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
| DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
| EP1165594A4 (de) | Antisens oligonucleotide-modulierung der stat3 expression | |
| ATE332369T1 (de) | Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens- oligonukleotide die an grb2 zielgerichtet sind | |
| DK1309726T3 (da) | RNA-sekvensspecifikke formidlere af RNA-interferens | |
| DE69920247D1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
| ATE488529T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| DE69927688D1 (de) | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs | |
| BR0008788A (pt) | Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase | |
| CA2417874A1 (en) | Use of ox-2 inhibitors for the treatment of cancer | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| EP0924296A3 (de) | Verfahren un Mittteln für die Induktion von Apoptosis durch Interferenz in RNS-Prozessierung | |
| EP1234877A4 (de) | Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie | |
| WO2001060998A3 (en) | Small oligonucleotides with anti-tumor activity | |
| IL163672A0 (en) | Microorganisms as carriers of nucleotide sequencescoding for cell antigens used for the treatment o f tumors | |
| AU2180501A (en) | Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide | |
| WO2005090572A3 (en) | Compositions and methods for treating pancreatic cancer | |
| WO2004015063A3 (en) | Amplification and overexpression of oncogenes | |
| EP1248795A4 (de) | Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors | |
| DE10346721A1 (de) | Oligonukleotide, diese enthaltende Mittel und deren Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |